Anthony Hayes Biography and Net Worth

CEO of Dominari

Anthony C. Hayes, Esq., is the driving force behind Dominari Holdings Inc's ambitious expansion plans. Taking a leading role in transforming Aikido from biotechnology to corporate enterprise has been just one of his many goals - now with DOMH listed on NASDAQ (ticker: DOMH) and diversified holdings encompassing financial services, emerging growth & legacy pharma, he will oversee this exciting new era.

Hayes is a renowned attorney who achieved great success in his fields of expertise. He rose to prominence, not only as partner at an Am Law 100 firm and co-founder/managing member of JaNSOME IP Management LLC – a consulting firm for intellectual property monetization best practices – but also garnered special recognition from President George W. Bush for creating the 501(c)(3) organisation 'Wills For Heroes'. His work has been acknowledged with other honours such as IAM's 2013 IP Personality Award, American Board of Trial Advocates' Young Lawyer Of The Year prize and Columbia South Carolina's "20 Under 40" award.

After earning an economics degree from Mary Washington College in 1990, he went on to get a Juris Doctor from Tulane University Law School and since then has become affiliated with Bar Memberships across four states. He has also published literature on the topic of post-crisis management.

What is Anthony Hayes' net worth?: The estimated net worth of Anthony Hayes is at least $11.79 million as of September 10th, 2026. Mr. Hayes owns 4,550,873 shares of Dominari stock worth more than $11,786,761 as of September 22nd. This net worth evaluation does not reflect any other assets that Mr. Hayes may own. Learn More about Anthony Hayes' net worth.
How do I contact Anthony Hayes?: The corporate mailing address for Mr. Hayes and other Dominari executives is 725 Fifth Avenue, 22nd Floor, New York, NY, 10022. Dominari can also be reached via phone at (212) 393-4540 and via email at [email protected]. Learn More on Anthony Hayes' contact information.
Has Anthony Hayes been buying or selling shares of Dominari?: Within the last three months, Anthony Hayes has bought $101,000.00 in Dominari stock. Most recently, on Thursday, September 10th, Anthony Hayes bought 50,000 shares of Dominari stock. The stock was acquired at an average cost of $2.02 per share, with a total value of $101,000.00. Following the completion of the transaction, the chief executive officer now directly owns 4,550,873 shares of the company's stock, valued at $9,192,763.46. Learn More on Anthony Hayes' trading history.
Are insiders buying or selling shares of Dominari?: During the last year, Dominari insiders bought shares 2 times. They purchased a total of 100,000 shares worth more than $202,000.00. During the last year, insiders at the sold shares 3 times. They sold a total of 225,000 shares worth more than $876,850.00. The most recent insider tranaction occured on September, 10th when CEO Anthony Hayes bought 50,000 shares worth more than $101,000.00. Insiders at Dominari own 55.3% of the company. Learn More about insider trades at Dominari.
Information on this page was last updated on 9/10/2026.

Anthony Hayes Insider Trading History at Dominari

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/10/2026	Buy	50,000	$2.02	$101,000.00	4,550,873
5/29/2024	Buy	1,158	$2.25	$2,605.50	219,664
4/4/2024	Buy	3,944	$2.62	$10,333.28	102,748
12/20/2023	Buy	70,000	$2.00	$140,000.00	98,804
11/24/2023	Buy	1,481	$2.16	$3,198.96	24,804
11/22/2023	Buy	1,323	$2.09	$2,765.07	23,323
11/16/2023	Buy	2,500	$1.97	$4,925.00	22,000
11/14/2023	Buy	2,500	$1.93	$4,825.00	19,500
9/20/2023	Buy	15,000	$2.59	$38,850.00	17,000
9/13/2023	Buy	2,000	$2.75	$5,500.00	2,000
8/23/2023	Buy	2,000	$2.86	$5,720.00	218,506
8/16/2023	Buy	2,000	$2.94	$5,880.00	216,506
6/13/2023	Buy	506	$2.89	$1,462.34	213,187
5/24/2023	Buy	2,000	$2.75	$5,500.00	212,681
5/16/2023	Buy	2,000	$2.77	$5,540.00	208,681
4/4/2023	Buy	30,000	$3.44	$103,200.00	206,681

Anthony Hayes Buying and Selling Activity at Dominari

Dominari Company Overview

Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.

Today's Range

Now: $2.56

$2.48

$2.60

50 Day Range

MA: $2.50

$1.94

$3.14

2 Week Range

Now: $2.56

$1.91

$8.40

Volume

372,049 shs

Average Volume

162,323 shs

Market Capitalization

$62.05 million

P/E Ratio

N/A

Dividend Yield